Examkin

Soru

Zorluk: OrtaMonitoring and Treatment Evaluation

A 6868-year-old man is evaluated in the cardiology clinic for a follow-up of heart failure with reduced ejection fraction. His left ventricular ejection fraction is 32%32\%. He is currently treated with sacubitril-valsartan, carvedilol, and furosemide. He reports mild exertional dyspnea but denies orthopnea or peripheral edema. Current vital signs are blood pressure 118/75 mmHg118/75\text{ mmHg} and heart rate 64/min64\text{/min}.

Laboratory studies from today show:
ParameterResult
Serum sodium139 mEq/L139\text{ mEq/L}
Serum potassium4.1 mEq/L4.1\text{ mEq/L}
Serum creatinine1.1 mg/dL1.1\text{ mg/dL}
Blood urea nitrogen19 mg/dL19\text{ mg/dL}

The physician decides to initiate spironolactone to further optimize his heart failure regimen. The patient is counseled on the new medication. Which of the following laboratory parameters are strictly recommended to be monitored 11 to 22 weeks after initiating this specific therapy? (Select 2)

  1. Serum potassiumCevap
  2. Serum creatinineCevap
  3. C
    N-terminal pro-B-type natriuretic peptide
  4. D
    Serum magnesium
  5. E
    Serum uric acid

Cevap

The correct parameters to monitor are Serum potassium and Serum creatinine.
The correct parameters to monitor are Serum potassium and Serum creatinine. Spironolactone is a mineralocorticoid receptor antagonist (MRA) that blocks aldosterone, leading to decreased potassium excretion and potential alterations in renal hemodynamics. When combined with an angiotensin receptor-neprilysin inhibitor (ARNI) like sacubitril-valsartan, the risk of hyperkalemia and acute kidney injury is substantially elevated. Clinical guidelines strictly mandate rechecking serum potassium and renal function (creatinine) 11 to 22 weeks after initiation or dose titration of an MRA to prevent life-threatening arrhythmias and renal failure.

Adım Adım Çözüm

1
Identify the new medication and its pharmacological class.
Spironolactone is a mineralocorticoid receptor antagonist (MRA).
Understanding the drug class is essential to predicting its physiological effects and adverse event profile.
2
Analyze the patient's concurrent medications for potential interactions.
The patient is taking sacubitril-valsartan, which contains an angiotensin II receptor blocker (ARB) that also inhibits the renin-angiotensin-aldosterone system (RAAS).
Concurrent use of multiple RAAS inhibitors multiplicatively increases the risk of specific adverse effects.
3
Determine the required monitoring based on the pharmacodynamic interaction.
The combination of an MRA and an ARB significantly increases the risk of severe hyperkalemia and acute kidney injury.
Clinical guidelines strictly mandate rechecking potassium and renal function 1 to 2 weeks after initiating an MRA to prevent life-threatening complications.

Anahtar Kavram

Patients initiated on mineralocorticoid receptor antagonists (e.g., spironolactone), especially those concurrently taking other RAAS inhibitors, require monitoring of serum potassium and renal function (creatinine) within 1 to 2 weeks to prevent severe hyperkalemia and acute kidney injury.
Tahmini Süre:1m 0s
Bu soruyu puanla

Konular

Monitoring and Treatment Evaluation

Bu konudan daha fazla soru